New results on lanifibranor to be presented at the International Liver Congress™ 2019
New results on lanifibranor to be presented at the International Liver Congress™ 2019
4 February 2019
Daix (France), February 4, 2019 – Inventiva S.A. (“Inventiva”), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (“NASH”), systemic sclerosis and mucopolysaccharidosis (“MPS”), today announced that the abstract submitted by Pr Frank Tacke[1] MD, PhD, to the European Association for the Study of the Liver comparing in a mouse model the effects on the disease characteristics of NASH of the pan-PPAR agonist lanifibranor against the effects of certain single PPARα, PPARγ and PPARδ agonists has been accepted for an oral presentation at the International Liver Congress™ 2019 (April 10-14, 2019, Vienna, Austria).
The study, led by Pr Frank Tacke, found that administration of lanifibranor was associated with a combination of beneficial effects on many NASH characteristics, as well as with more potent effects on inflammation and disease progression than the tested single PPAR agonists. More specifically, administration of lanifibranor was associated with increased circulating adiponectin, reduced triglycerides and attenuated hepatocyte ballooning. Additionally, administration of lanifibranor and, to a lesser extent the tested single PPARa agonist, were associated with improvements in steatosis and lobular inflammation. Administration of lanifibranor was also associated with a more pronounced improvement of fibrosis than all of the other tested single PPAR agonists, suggesting that lanifibranor may combine the beneficial effects of single PPAR agonists and may counter inflammation and disease progression more potently. As a result, the study suggests that pan-PPAR agonists, such as lanifibranor, have the potential for more therapeutic effectiveness than single-PPAR agonists in the treatment of NASH.
The abstract, which is entitled “Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis,” will be presented on April 11th. The details of the presentation are as follows:
Event: International Liver Congress™ 2019, Vienna, Austria
Date: Thursday, April 11th, 2019
Time of the presentation: 5.30 pm to 5.45 pm (Central European Time)
Session: NAFLD Pathophysiology – Target identification
Speakers: Sander Lefere[2]
Background on PPARs
Peroxisome proliferator-activated receptors (“PPARs”) are nuclear receptors essential for the regulation of glucose and lipid metabolism in the liver and adipose tissue. They are also expressed in immune cells, notably macrophages, where they act as modulators of inflammation and fibrogenesis. Various single or dual PPAR agonists have been clinically evaluated in NASH, yielding variable effects on aspects of NASH pathogenesis.
[1] Dept. of Gastroenterology, Metabolic Diseases and Intensive Care Medicine, University Hospital Aachen, Germany / Department of Hepatology/Gastroenterology, Charité University Medical Center, Berlin, Germany
[2]PhD student, Ghent University
Contacts
Inventiva
Frédéric Cren
Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00
Brunswick
Julien Trosdorf / Yannick Tetzlaff
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83
LifeSci Advisors
Monique Kosse
Investor relations
monique@lifesciadvisors.com
Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.
Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.
Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.[/lvca_panel][lvca_panel panel_id=”panel-5bc0ba5831260″ panel_title=”Important Notice”]This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.
There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.
Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.[/lvca_panel][/lvca_accordion]
